---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-24-000122"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:23:31.993235+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q2 product revenue $30.9M, up 547% YoY; net loss narrows to $52.3M

## Summary
- ZORYVE franchise net product revenue $30.9M ($17.3M cream, $13.6M foam); 43% sequential growth.
- Net loss $52.3M ($0.42/share) vs $71.0M loss in Q2 2023; cash $363.1M.
- Entered co-promotion with Kowa Pharmaceuticals for primary care and pediatric promotion of ZORYVE.
- Submitted sNDA for ZORYVE foam for scalp/body psoriasis; FDA approved cream 0.15% for atopic dermatitis.
- Amended $200M term loan: rate reduced 150bps, maturity extended to June 2029, $100M prepay/re-draw option.

## SEC filing metadata
- accession: 0001787306-24-000122
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000122/0001787306-24-000122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000122/arqt-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-24-000122
- JSON: https://secwatch.observer/filing/0001787306-24-000122.json
- Plain text: https://secwatch.observer/filing/0001787306-24-000122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.